Movement disorders:帕金森患者,糖尿病可加速其进展

2022-06-26 Freeman MedSci原创

T2DM与帕金森病的疾病进展速度有关,突出了这两种疾病之间的互动。

帕金森病(PD)影响着全世界600万人,而且随着人口老龄化的到来,其发病率预计会增加。尽管衰老无疑是最重要的风险因素,但有证据表明2型糖尿病(T2DM)是一个适度的风险因素。此外,越来越多的证据表明,这些疾病有共同的生物机制,并有共同的遗传联系,突出了胰岛素信号传导失调可能是导致这些疾病之间关联的一个聚合途径。

图1: 论文封面图

胰岛素受体在整个大脑中广泛表达,在PD、多系统萎缩和阿尔茨海默病(AD)的尸检研究中发现了神经元胰岛素信号传导缺陷的证据。胰岛素信号传导的缺陷导致主要下游途径的功能障碍,包括Akt和丝裂原活化蛋白激酶途径。这些途径反过来又调节着维持神经元生存所必需的各种过程,包括自噬、蛋白质合成、炎症、神经细胞代谢以及多巴胺的合成和清除,所有这些在PD中都会被破坏,因此可能被合并的T2DM所加剧/触发。与没有T2DM的患者相比,PD+T2DM患者在尾状体和腹侧纹状体表现出更严重的多巴胺能耗竭,以及更多的额颞叶皮质萎缩,进一步支持胰岛素抵抗对神经变性的影响。

除了对PD风险的影响外,少数研究还评估了T2DM对疾病进展的影响,认为与没有T2DM的PD患者相比,合并T2DM可能与运动和认知能力的快速下降有关。然而,这些研究的普遍性由于所包括的患者数量较少而受到限制。

藉此,英国Francis Crick Institute的Dilan Athauda等人,利用跟踪帕金森病队列这一大型的PD长期观察研究,目的是首先评估最近被诊断为PD的患者中合并T2DM与PD严重程度的关系,其次是确定T2DM是否对疾病进展产生负面影响。

他们分析了跟踪帕金森病研究的数据,通过比较评估一系列运动和非运动症状的症状严重程度,研究合并T2DM对PD进展和生活质量的影响。

他们确定了167名(8.7%)PD和T2DM(PD+T2DM)患者和1763名(91.3%)无T2DM(PD)的PD患者。

在控制了混杂因素后,T2DM患者有更严重的运动症状,根据运动障碍协会统一帕金森病评定量表第三部分评估(25.8 [0.9] vs. 22.5 [0.3] P = 0.002),以及非运动症状,根据非运动症状量表总数评估(38. 4 [2.5] vs. 31.8 [0.7] P <0.001),并且明显更有可能报告丧失独立性(几率比,2.08;95%置信区间[CI]:1.34-3.25;P = 0.001)和抑郁症(几率比,1.62;CI:1.10-2.39;P = 0.015)。

 

图2:论文结果图

 

此外,随着时间的推移,与PD组相比,T2DM患者的运动症状进展明显加快(P = 0.012),情绪症状恶化(P = 0.041),并且更有可能出现实质性步态障碍(危险比,1.55;CI:1.07-2.23;P = 0.020)和轻度认知障碍(危险比,1.7;CI:1.24-2.51;P = 0.002)。

该研究的重要意义在于发现了:T2DM与帕金森病的疾病进展速度有关,突出了这两种疾病之间的互动。因为它是一种潜在的可改变的代谢状态,有多个外周和中枢的干预目标,它可能是缓解帕金森病症状和延缓残疾和痴呆进展的目标。


原文出处:

Athauda D, Evans J, Wernick A, et al. The Impact of Type 2 Diabetes in Parkinson’s Disease. _Movement Disorders_. Published online June 14, 2022:mds.29122. doi:[10.1002/mds.29122](https://doi.org/10.1002/mds.29122)

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2077705, encodeId=1c5b20e77058b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Dec 13 21:06:39 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784522, encodeId=dcf61e845225f, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 17:06:39 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738137, encodeId=360c1e3813785, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Tue Jul 26 01:06:39 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878547, encodeId=db2b18e854778, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Sep 29 03:06:39 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239910, encodeId=da651239910d4, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:03:56 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013912, encodeId=6d1020139126c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 09 04:06:39 CST 2022, time=2022-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2077705, encodeId=1c5b20e77058b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Dec 13 21:06:39 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784522, encodeId=dcf61e845225f, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 17:06:39 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738137, encodeId=360c1e3813785, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Tue Jul 26 01:06:39 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878547, encodeId=db2b18e854778, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Sep 29 03:06:39 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239910, encodeId=da651239910d4, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:03:56 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013912, encodeId=6d1020139126c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 09 04:06:39 CST 2022, time=2022-10-09, status=1, ipAttribution=)]
    2023-01-29 cmsvly

    #Disord#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2077705, encodeId=1c5b20e77058b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Dec 13 21:06:39 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784522, encodeId=dcf61e845225f, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 17:06:39 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738137, encodeId=360c1e3813785, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Tue Jul 26 01:06:39 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878547, encodeId=db2b18e854778, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Sep 29 03:06:39 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239910, encodeId=da651239910d4, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:03:56 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013912, encodeId=6d1020139126c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 09 04:06:39 CST 2022, time=2022-10-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2077705, encodeId=1c5b20e77058b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Dec 13 21:06:39 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784522, encodeId=dcf61e845225f, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 17:06:39 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738137, encodeId=360c1e3813785, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Tue Jul 26 01:06:39 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878547, encodeId=db2b18e854778, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Sep 29 03:06:39 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239910, encodeId=da651239910d4, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:03:56 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013912, encodeId=6d1020139126c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 09 04:06:39 CST 2022, time=2022-10-09, status=1, ipAttribution=)]
    2022-09-29 anminleiryan

    #ERS#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2077705, encodeId=1c5b20e77058b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Dec 13 21:06:39 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784522, encodeId=dcf61e845225f, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 17:06:39 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738137, encodeId=360c1e3813785, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Tue Jul 26 01:06:39 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878547, encodeId=db2b18e854778, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Sep 29 03:06:39 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239910, encodeId=da651239910d4, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:03:56 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013912, encodeId=6d1020139126c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 09 04:06:39 CST 2022, time=2022-10-09, status=1, ipAttribution=)]
    2022-08-20 laiminchao

    学习了,多谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2077705, encodeId=1c5b20e77058b, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Tue Dec 13 21:06:39 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784522, encodeId=dcf61e845225f, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 17:06:39 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738137, encodeId=360c1e3813785, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Tue Jul 26 01:06:39 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878547, encodeId=db2b18e854778, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Sep 29 03:06:39 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1239910, encodeId=da651239910d4, content=学习了,多谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9c3032606, createdName=laiminchao, createdTime=Sat Aug 20 08:03:56 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013912, encodeId=6d1020139126c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Oct 09 04:06:39 CST 2022, time=2022-10-09, status=1, ipAttribution=)]
    2022-10-09 cmj8wellington

    #Dis#

    0

相关资讯

Movement disorder:-帕金森患者,大脑代谢和步态有何关系?

两个新的与步态有关的大脑网络,在静止状态下葡萄糖代谢发生了改变

Movement disorders:帕金森氏征,多巴胺代谢和大脑血流代谢有何关系?

在PD和四次重复的tauopathy中,前额叶灌注与同侧黑质多巴胺能功能有关

Cell:徐浩新/胡美钦/李平/王策等揭示帕金森病发病风险的新机制

该研究开辟了溶酶体 pH 调节的新方向,首次鉴定出溶酶体膜上的氢离子通道:TMEM175 是一种新型的氢离子激活的氢离子通道。

MOVEMENT DISORDERS:2型糖尿病与帕金森病更快进展有关

T2DM与帕金森病更快的疾病进展有关,它可能是缓解帕金森症状和减缓残疾和痴呆进展的目标。

Science Translational Medicine:帕金森病治疗的一大步:LRRK2抑制剂临床试验评估

全世界有超过1000万人患有帕金森病,每年还有约60000名新患者确诊。患者大脑中产生多巴胺的神经元丧失,影响运动和认知,导致出现震颤、肌肉僵硬、意识模糊和痴呆等症状。

拓展阅读

Movement Disorders:帕金森病患者吞咽功能特征综述

本综述纳入46项研究共1797例帕金森病患者,识别出19项在至少两项研究中一致存在的口咽期吞咽特征改变,主要表现为口腔期与咽期的运动减慢、幅度减小及吞咽启动延迟,而食管期证据尚不充分。

专访上海市第一人民医院桂雅星教授:帕金森病治疗新策略,靶向谷氨酸能系统 | 第十五届东方神经病学会议

梅斯医学专访上海市第一人民医院桂雅星教授,围绕谷氨酸能系统在帕金森病中的病理角色、临床转化进展及个体化医疗应用展开深度对话,为临床治疗策略优化提供核心参考。

eBioMedicine:经颅时间干扰刺激为帕金森病运动症状治疗开辟新路径

靶向丘脑底核区域的单次经颅时间干扰刺激安全可行,能有效改善中早期帕金森病患者的运动症状,尤其对运动迟缓、震颤效果显著。

Neurology揭示帕金森病静息震颤与多巴胺转运体的核心关联

该研究在临床样本中验证了PD患者静息震颤与同侧纹状体DAT结合率的关联,为PD静息震颤的病理生理机制研究提供了重要临床依据。

eBioMedicine:帕金森病患者血液微生物信号显著异常,19种变形菌门细菌或成诊断新靶点

该研究首次通过大规模多队列WGS分析,证实PD患者血液中存在显著异常的微生物特征,明确19种细菌可作为潜在生物标志物,为PD的诊断和病情评估提供了新靶点。

帕金森病核心病理难追踪?【Cell】曹鹏团队给α-Syn聚集体装上“荧光追踪器”

本研究开发的α-Syn可视化报告系统可实现:检测α-Syn聚集体对神经元活动的影响;评估其诱导的神经元病理改变;标记不同类型神经元中的α-Syn聚集体;筛选抑制α-Syn包涵体形成的化合物。

2026 最佳实践指南:帕金森病认知障碍的诊断、评估和管理

国外神经内科相关专家小组(统称) · 2026-03-16

NEJM综述:帕金森病(2024)

暂未更新 · 2024-08-01